Ximena Jordan Bruno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ximena Jordan Bruno has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Narjust Florez
Dana-Farber Cancer Institute, Boston, USA
2 shared publications - Alba J. Kihn-Alarcón
Research Department, Liga Nacional Contra el Cáncer & Instituto de Cancerología, Guatemala City, Guatemala
1 shared publication Allen B. Repp
Department of Medicine Larner College of Medicine University of Vermont Burlington Vermont USA
1 shared publicationAlvaro Menendez
Hartford HealthCare, Hartford, CT
1 shared publication- Ana I. Velazquez
University of California, San Francisco, CA
1 shared publication - Benjamin Aaron Bleiberg
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
1 shared publication
Latest Publications
- 5 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Evaluating Artificial Intelligence Translation Tools for Language Equivalence of Oncology-Informed Consent Forms From English to Spanish
PURPOSE: Approximately 8% of the US population speaks primary languages other than English. Limited English proficiency (LEP) contributes to under-representation of Hispanic patients in oncology clinical trials. Although certified translation services exist, they are time-consuming and costly. Artificial intelligence (AI)–generated translations of informed consent forms (ICFs) could provide low-cost alternatives, but data on accuracy and safety remain limited. We evaluated language equivalence of English-to-Spanish translations for three oncology clinical trial ICFs using two general-purpose AI translation tools (DeepL Pro and ChatGPT-4o) and a medically trained AI translation tool (Med_English2Spanish) compared with certified translations. METHODS: Translational equivalence was assessed using a five-point Likert scale on five domains: Semantic, Idiomatic, Experiential, Conceptual, and Safety. Two native Spanish-speaking bilingual board-certified physicians independently scored each translation. Weighted Cohen's kappa determined inter-rater reliability, and the two-sample t-test compared AI-generated and certified translations. RESULTS: Weighted Cohen's kappa (0.95, 95% CI 0.85 to 0.97) exhibited high inter-rater agreement. Certified translations exhibited the highest equivalence (mean = 4.99, SD = 0.02). ChatGPT-4o similarly demonstrated high equivalence (mean = 4.89, SD = 0.17). DeepL Pro scored well (mean = 4.43, SD = 0.07) but lower than certified translation ( P < 0.001). Med_English2Spanish demonstrated the lowest degree of equivalence (mean = 3.32, SD = 0.40) compared with certified translations ( P < 0.001). CONCLUSION: Low-cost AI translations of ICFs exhibited variable language equivalence compared with certified translations across several domains. ChatGPT-4o scored nearly equivalent across domains in translating procedural trial information. While AI-generated translations are currently not suitable for clinical deployment without human review, this exploratory study supports further analysis of AI translation tools for reducing language barriers to LEP population enrollment.
- 5 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Evaluating Artificial Intelligence Translation Tools for Language Equivalence of Oncology-Informed Consent Forms From English to Spanish
PURPOSE: Approximately 8% of the US population speaks primary languages other than English. Limited English proficiency (LEP) contributes to under-representation of Hispanic patients in oncology clinical trials. Although certified translation services exist, they are time-consuming and costly. Artificial intelligence (AI)–generated translations of informed consent forms (ICFs) could provide low-cost alternatives, but data on accuracy and safety remain limited. We evaluated language equivalence of English-to-Spanish translations for three oncology clinical trial ICFs using two general-purpose AI translation tools (DeepL Pro and ChatGPT-4o) and a medically trained AI translation tool (Med_English2Spanish) compared with certified translations. METHODS: Translational equivalence was assessed using a five-point Likert scale on five domains: Semantic, Idiomatic, Experiential, Conceptual, and Safety. Two native Spanish-speaking bilingual board-certified physicians independently scored each translation. Weighted Cohen's kappa determined inter-rater reliability, and the two-sample t-test compared AI-generated and certified translations. RESULTS: Weighted Cohen's kappa (0.95, 95% CI 0.85 to 0.97) exhibited high inter-rater agreement. Certified translations exhibited the highest equivalence (mean = 4.99, SD = 0.02). ChatGPT-4o similarly demonstrated high equivalence (mean = 4.89, SD = 0.17). DeepL Pro scored well (mean = 4.43, SD = 0.07) but lower than certified translation ( P < 0.001). Med_English2Spanish demonstrated the lowest degree of equivalence (mean = 3.32, SD = 0.40) compared with certified translations ( P < 0.001). CONCLUSION: Low-cost AI translations of ICFs exhibited variable language equivalence compared with certified translations across several domains. ChatGPT-4o scored nearly equivalent across domains in translating procedural trial information. While AI-generated translations are currently not suitable for clinical deployment without human review, this exploratory study supports further analysis of AI translation tools for reducing language barriers to LEP population enrollment.
- 1 October 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (10) , 899-906
Parent Penalty: Parental Leave Experiences of Trainees and Early-Career Faculty in Oncology Subspecialties
Oncology trainee/early-career faculty survey shows inadequate parental leave/lactation policies #parentpenalty
- 1 October 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (10) , 899-906
Parent Penalty: Parental Leave Experiences of Trainees and Early-Career Faculty in Oncology Subspecialties
Oncology trainee/early-career faculty survey shows inadequate parental leave/lactation policies #parentpenalty
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 333
Family history screening following new diagnoses of leukemia versus solid malignancies.
333 Background: Family history screening for malignancies informs the need for genetic testing of cancer patients and their families. Associations between heritable mutations and solid malignancies are well-established, but germline contributions to hematologic malignancies may be of similar importance. For instance, the pooled risk of a group of heritable transcription factor mutations including RUNX1, GATA2, and CEBPA may play a role in up to 15% of new cases of leukemia. Standard of care for new patient visits in malignant hematology clinics should involve thorough family screening like that of solid malignancies more classically associated with heredity. Methods: All patients presenting to an academic hospital system's outpatient GI, breast, and leukemia clinics for new patient visits in a 3-month period were identified accounting for 706 participants (breast n=258 (36.5%), GI n=303 (42.9%), leukemia n=145 (20.5%)). Retrospective chart review was completed by EMR report, which aggregated data from individuals identified by their cancer diagnosis. Groups were compared along the following variables: percentage with completed 1st degree (parents and siblings) family history of malignancy screening, percentage with completed 2nd degree (grandparents, aunts, and uncles) family history screening. Chi-squared significance testing was completed to identify significant (pst degree family history of malignancy screening than those presenting with new diagnoses of leukemia (62.1%). The comparison of 1st degree screening for GI (71.6%) cancer patients and leukemia patients was not significant. Rates of 2nd degree family history screening were significantly higher for patients with new diagnoses of breast (61.6%) and GI (37.0%) cancers as compared to those with leukemia (24.8%). The combined cohort of GI and breast cancer patients had significantly greater rates of 1st (74.2%) and 2nd degree (48.4%) family history screening than patients with new diagnosis of leukemia. Conclusions: There is growing appreciation of heritable germline contributors to leukemia pathogenesis. However, there remains a deficit in clearly documented, easily referenced family history screening for malignancies in patients with new diagnoses of leukemia when compared to patients with new diagnoses of classically heritable solid malignancies.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 333
Family history screening following new diagnoses of leukemia versus solid malignancies.
333 Background: Family history screening for malignancies informs the need for genetic testing of cancer patients and their families. Associations between heritable mutations and solid malignancies are well-established, but germline contributions to hematologic malignancies may be of similar importance. For instance, the pooled risk of a group of heritable transcription factor mutations including RUNX1, GATA2, and CEBPA may play a role in up to 15% of new cases of leukemia. Standard of care for new patient visits in malignant hematology clinics should involve thorough family screening like that of solid malignancies more classically associated with heredity. Methods: All patients presenting to an academic hospital system's outpatient GI, breast, and leukemia clinics for new patient visits in a 3-month period were identified accounting for 706 participants (breast n=258 (36.5%), GI n=303 (42.9%), leukemia n=145 (20.5%)). Retrospective chart review was completed by EMR report, which aggregated data from individuals identified by their cancer diagnosis. Groups were compared along the following variables: percentage with completed 1st degree (parents and siblings) family history of malignancy screening, percentage with completed 2nd degree (grandparents, aunts, and uncles) family history screening. Chi-squared significance testing was completed to identify significant (pst degree family history of malignancy screening than those presenting with new diagnoses of leukemia (62.1%). The comparison of 1st degree screening for GI (71.6%) cancer patients and leukemia patients was not significant. Rates of 2nd degree family history screening were significantly higher for patients with new diagnoses of breast (61.6%) and GI (37.0%) cancers as compared to those with leukemia (24.8%). The combined cohort of GI and breast cancer patients had significantly greater rates of 1st (74.2%) and 2nd degree (48.4%) family history screening than patients with new diagnosis of leukemia. Conclusions: There is growing appreciation of heritable germline contributors to leukemia pathogenesis. However, there remains a deficit in clearly documented, easily referenced family history screening for malignancies in patients with new diagnoses of leukemia when compared to patients with new diagnoses of classically heritable solid malignancies.
- Open Access
- 15 April 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (7) , 1645-1652
Venous thrombosis risk during and after medical and surgical hospitalizations: The medical inpatient thrombosis and hemostasis (MITH) study
- 15 April 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (7) , 1645-1652
Open AccessVenous thrombosis risk during and after medical and surgical hospitalizations: The medical inpatient thrombosis and hemostasis (MITH) study
- Open Access
- 4 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2100251
HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America
PURPOSE: The HOLA COVID-19 study sought to evaluate the impact of COVID-19 on oncology practices across Latin America (LATAM), challenges faced by physicians, and how practices and physicians adapted while delivering care to patients with cancer.METHODS: This international cross-sectional study of oncology physicians in LATAM included a 43-item anonymous online survey to evaluate changes and adaptations to clinical practice. Multivariable logistic regression analyses were used to evaluate the association of caring for patients with COVID-19 and changes to clinical practice.RESULTS: A total of 704 oncology physicians from 19 countries completed the survey. Among respondents, the most common specialty was general oncology (34%) and 56% of physicians had cared for patients with COVID-19. The majority of physicians (70%) noted a decrease in the number of new patients evaluated during the COVID-19 pandemic when compared with prepandemic, and 73% reported adopting the use of telemedicine in their practice. More than half (58%) of physicians reported making changes to the treatments that they offered to patients with cancer. In adjusted models, physicians who had cared for patients with COVID-19 had higher odds of changing the type of chemotherapy or treatments that they offered (adjusted odds ratio 1.81; 95% CI, 1.30 to 2.53) and of delaying chemotherapy start (adjusted odds ratio 2.05; 95% CI, 1.49 to 2.81). Physicians identified significant delays in access to radiation and surgical services, diagnostic tests, and supportive care.CONCLUSION: The COVID-19 pandemic has significantly disrupted global cancer care. Although changes to health care delivery are a necessary response to this global crisis, our study highlights the significant disruption and changes to the treatment plans of patients with cancer in LATAM resulting from the COVID-19 health care crisis.
- 4 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2100251
Open AccessHOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America
PURPOSE: The HOLA COVID-19 study sought to evaluate the impact of COVID-19 on oncology practices across Latin America (LATAM), challenges faced by physicians, and how practices and physicians adapted while delivering care to patients with cancer.METHODS: This international cross-sectional study of oncology physicians in LATAM included a 43-item anonymous online survey to evaluate changes and adaptations to clinical practice. Multivariable logistic regression analyses were used to evaluate the association of caring for patients with COVID-19 and changes to clinical practice.RESULTS: A total of 704 oncology physicians from 19 countries completed the survey. Among respondents, the most common specialty was general oncology (34%) and 56% of physicians had cared for patients with COVID-19. The majority of physicians (70%) noted a decrease in the number of new patients evaluated during the COVID-19 pandemic when compared with prepandemic, and 73% reported adopting the use of telemedicine in their practice. More than half (58%) of physicians reported making changes to the treatments that they offered to patients with cancer. In adjusted models, physicians who had cared for patients with COVID-19 had higher odds of changing the type of chemotherapy or treatments that they offered (adjusted odds ratio 1.81; 95% CI, 1.30 to 2.53) and of delaying chemotherapy start (adjusted odds ratio 2.05; 95% CI, 1.49 to 2.81). Physicians identified significant delays in access to radiation and surgical services, diagnostic tests, and supportive care.CONCLUSION: The COVID-19 pandemic has significantly disrupted global cancer care. Although changes to health care delivery are a necessary response to this global crisis, our study highlights the significant disruption and changes to the treatment plans of patients with cancer in LATAM resulting from the COVID-19 health care crisis.